Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.55 |
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | UNG | P13051 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30800165 | 1.00 | MAOA (0.55) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL23430770 | 0.90 | ERN1 (0.57) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL6781940 | 0.86 | MAOA (0.50) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL21153827 | 0.85 | NPC1 (0.50) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL254407 | 0.85 | MAOA (0.53) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1818624 | 0.82 | ERN1 (0.39) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2811803 | 0.81 | MAOA (0.46) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL31591062 | 0.81 | MAOA (0.46) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL7672328 | 0.81 | MAOA (0.53) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL12152655 | 0.81 | NPC1 (0.52) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112210056-B | Porous covalent organic framework material and synthesis method and application thereof | 台州学院 | 2022-12-02 | — | — | CN | claimed |
| CN-112210056-A | Porous covalent organic framework material and synthesis method and application thereof | 台州学院 | 2021-01-12 | — | — | CN | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| CN-112513188-B | Coelenterazine analogs | 普洛麦格公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| CN-112210056-B | Porous covalent organic framework material and synthesis method and application thereof | 台州学院 | 2022-12-02 | — | — | CN | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-08-29 | — | — | US | disclosed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | disclosed |
| EP-1122253-A1 | QUINAZOLINONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | disclosed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | MAOA 3004/4885MAOB 1696/4885NPC1 1085/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAOA 3004/4885MAOB 1696/4885NPC1 1085/4885 |
| US-20020120011-A1 | Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, DBI | MAOA 2106/4885MAOB 1480/4885NPC1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.